Topical Spironolactone in the Treatment of Ocular Graft-Versus-Host Disease

This study suggests that topical spironolactone may be effective in treating ocular graft-versus-host disease (oGVHD) by promoting lipid production in the corneal epithelium, which could protect against ocular surface erosive disease. In vitro and in vivo experiments demonstrated increased lipid synthesis in corneal tissues treated with spironolactone. Clinically, 20 oGVHD patients treated with topical spironolactone showed significant improvements in lid margin vascularity, corneal fluorescein staining, and disease severity scores, with minimal adverse effects. These findings support the potential therapeutic benefits of spironolactone for oGVHD, though further research with larger sample sizes is needed.